Abstract:Objective: To investigate the influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran.Study design: This was an open-label, randomised, 3 × 3 crossover study with 4 study days, separated by washout periods of 7 days.Subjects: Subjects comprised 6 healthy young men (aged 20–27 years) and 12 healthy older men and women (aged 56–70 years).Methods: All subjects received a 2mg intravenous infusion of melagatran over 10 minutes followed, in randomised sequence, by a 20mg immediate-release tablet of ximelagatran with breakfast, a 20mg immediate-release tablet of ximelagatran while fasting, and a 7.5mg subcutaneous injection of ximelagatran. The primary variables were the plasma concentration of melagatran, the active form of ximelagatran, and the activated partial thromboplastin time (APTT), an ex vivo coagulation time measurement used to demonstrate inhibition of thrombin.Results: After oral and subcutaneous administration, ximelagatran was rapidly absorbed and biotransformed to melagatran, its active form and the dominant compound in plasma. The metabolite pattern in plasma and urine was similar in young and older subjects after both oral and subcutaneous administration of ximelagatran. Clearance of melagatran was correlated with renal function, resulting in about 40% (after intravenous melagatran) to 60% (after oral and subcutaneous ximelagatran) higher melagatran exposure in the older than in the young subjects. Renal clearance of melagatran, determined after intravenous administration of melagatran, was 7.7 L/h and 4.9 L/h in the young and older subjects, respectively. The interindividual variability in the area under the melagatran plasma concentration-time curve was low following all regimens (coefficient of variation 12–25%). The mean bioavailability of melagatran in young and older subjects was approximately 18 and 21%, respectively, following oral administration of ximelagatran, and 38 and 45%, respectively, following subcutaneous administration of ximelagatran. The bioavailability of melagatran following oral administration of ximelagatran was unaffected by whether subjects were fed or fasting, although the plasma concentration of melagatran peaked about 1 hour later under fed than fasting conditions, due to delayed gastric emptying of the immediate-release tablet formulation used. The APTT was prolonged with increasing melagatran plasma concentrations and the concentration-effect relationship was independent of age.Conclusion: There were no age-dependent differences in the absorption and biotransformation of ximelagatran, and the observed differences in exposure to melagatran can be explained by differences in renal function between the young and older subjects.

Pharmacokinetics of Trantinterol and Its Metabolite in Healthy Elderly and Young Subjects

Tolerability and Pharmacokinetics of Tratinterol Hydrochloride Tablets in Healthy Subjects after a Single Dose Administration

Aging and antioxidants: the impact of dietary carotenoid intakes on soluble klotho levels in aged adults

Population Pharmacokinetic/Pharmacodynamic Modeling of O-Desmethyltramadol in Young and Elderly Healthy Volunteers

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition

Population Pharmacokinetics of Propofol Administered by TCI in Chinese Elderly Patients

STEREOSELECTIVITY IN PHARMACOKINETICS OF THE ENANTIOMERS OF TRANS TRAMADOL

A Single-Center, Randomized, Open-Label, Dose-Escalation Study to Evaluate the Pharmacokinetics of Tacrine Analogue Octahydrogenacridine Succinate Tablets in Healthy Chinese Subjects

Population Pharmacokinetic Modeling and Simulation of Huperzine A in Elderly Chinese Subjects

Pharmacokinetics of Vancomycin in Elderly and Young Healthy Volunteers

Pharmacokinetics of the enantiomers of trans-tramadol and its active metabolite, trans-O-demethyltramadol, in healthy male and female chinese volunteers.

Pharmacokinetics and Bioequivalence Evaluation of Trazodone Hydrochloride Sustained‐Release Tablets in Healthy Chinese Volunteers

Pharmacokinetics and drug metabolism in the elderly

Current status and usefulness of therapeutic drug monitoring implementation of theophylline in elderly patients based on a nationwide database study and modeling approach

Age-related pharmacokinetics differences were observed between young and elderly populations of a novel PDE5 inhibitor, youkenafil, and its metabolite M459

Vinpocetine pharmacokinetics in elderly subjects

Theophylline-ranitidine interaction in elderly COPD patients

Pharmacokinetics of Enantiomers of Trans-Tramadol and Its Active Metabolite, Trans-O-demethyltramadol, in Human Subjects.

Population pharmacokinetics of theophylline in elderly patients with chronic obstructive pulmonary disease

Effects of testosterone replacement therapy on glycometabolism and lipid metabolism in aged male patients